Asparkam-L - instructions for use, dose, side effects, contraindications

Elimination of potassium and magnesium deficiency, normalization of electrolyte balance, improvement of metabolism in the myocardium. The mechanism of action of the drug is associated with effective participation L-aspraginate in the transport of magnesium and potassium ions into the intracellular space.

Magnesium activates sodium potassium-ATPase, removing sodium ions from the cell and returning the potassium ions; reduces the sodium content and prevents its exchange with calcium in the smooth muscle of the vessels, reducing their resistance.Potassium stimulates the synthesis of adenosine triphosphate, glycogen, proteins, acetylcholine, etc. Both ions support the polarization of / cell membranes. The drug regulates the conduct of impulses along nerve fibers, synaptic transmission, muscle contraction, the work of the heart muscle. Due to magnesium ions, it participates in the processes of energy intake and expenditure, normalizes membrane permeability, neuromuscular conductivity, synthesis of deoxyribonucleic and ribonucleic acids, cell growth, cell division, oxygen uptake, and synthesis of phosphates.

Pharmacokinetics:The ions of potassium and magnesium are rapidly absorbed and distributed throughout the tissues of the body. About 30% of magnesium in the plasma forms complex compounds with proteins. The excretion of potassium and magnesium occurs mainly by the kidneys, in small amounts - through the intestine, then, by tears, etc. In renal failure, excretion of potassium and magnesium ions can be slowed down.

Indications:

To eliminate the deficiency of potassium and magnesium as an auxiliary in complex therapy for various manifestations of coronary heart disease,including acute myocardial infarction; chronic heart failure; disorders of the rhythm of the heart (arrhythmias caused by an overdose of cardiac glycosides).

Contraindications:Hypersensitivity to the drug, sorbitol, hyperkalemia, hypermagnesia, acute renal failure, insufficiency of the adrenal cortex, atrioventricular blockade of grade II and III, impaired metabolism of amino acids, hemolysis, severe myasthenia gravis, dehydration; Addison's disease, age under 18 years (efficacy and safety of the drug are not established).

Carefully:Expressed violations of the liver, metabolic acidosis, the risk of edema, chronic renal failure, if the regular monitoring of the content of magnesium in the serum is impossible (danger of cumulation, toxic magnesium content), cardiogenic shock (systolic blood pressure less than 90 mm Hg), hypophosphatemia, urolithiasis, associated with a violation of the exchange of calcium, magnesium and ammonium phosphate, atrioventricular blockade of the I degree.

Pregnancy and lactation:The use of the drug during pregnancy and during breastfeeding is contraindicated (efficacy and safety not established).

Dosing and Administration:

The drug is administered intravenously (by drip or jet).

The dose of the drug is determined individually, depending on the indications for use.

Intravenously drip slowly injected at a rate of 25 drops per minute 1-2 times a day for 10-20 ml (1-2 ampules of 10 ml or 2-4 ampoules of 5 ml), diluted in 100-200 ml - 0.9% solution of sodium chloride, or in the same volume 5,% solution of dextrose (glucose).

When sprayed, the contents 1 ampoule of 10 ml or 2 ampoules of 5 ml diluted in 20 ml of sterile water for injection or 5% solution of dextrose (glucose) and injected slowly (not more than 5 ml per minute).

Side effects:

With rapid intravenous administration, all symptoms of hyperkalemia and hypermagnesemia:

Hyperkalemia (nausea, vomiting, diarrhea, paresthesia) and hypermagnia (facial skin hyperemia, thirst, bradycardia, lowering blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions); at parenteral introduction - atrioventricular blockade, paradoxical reaction (increase in the number of extrasystoles), phlebitis.

Overdose:

Symptoms: hyperkalemia (bradycardia, arrhythmia, drop in arterial pressure, vascular collapse, diastolic cardiac arrest - cardiac arrest during diastole with an increase in potassium in the serum above 6.0 mmol / l) and hypermagnesia (nausea, vomiting, respiratory depression and central nervous system).

Treatment: abolition of the drug, intravenous administration of calcium and sodium preparations.

In the presence of renal failure, extrarenal excretion can be achieved by hemodialysis or peritoneal dialysis.

Interaction:

Potassium-sparing diuretics (triamterene, spironolactone), beta-blockers, ciclosporin, heparin, angiotensin converting enzyme inhibitors, non-steroidal anti-inflammatory drugs - the risk of hyperkalemia development up to the development of - arrhythmia and asystole.

Eliminates hypokalemia caused by glucocorticosteroids.

Reduces unwanted effects of cardiac glycosides.

Due to the content of magnesium ions reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin.

Anesthetics increase the inhibitory effect of magnesium on the central nervous system.May enhance neuromuscular blockade caused by depolarizing muscle relaxants (atracurium bezylate, decamethonium bromide, suxamethonium (chloride, bromide, iodide)).

Calcitriol increases the concentration of magnesium in the blood plasma, calcium preparations - reduce the effect of magnesium.

The solution is pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerability).

Effect on the ability to drive transp. cf. and fur:

Studies to evaluate the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions have not been carried out.

Form release / dosage:Solution for intravenous administration.

Packaging:

5 ml or 10 ml in ampoules.

5 ampoules are placed in a contour mesh package made of a polyvinyl chloride film.

For 1, 2 contour mesh packages are placed in a pack of cardboard.

10 ampoules of 10 ml each are placed in a cardboard box with corrugated paper partitions.

In each pack, the box is attached instruction for use, ampoule knife or scarifier ampoule.At packing of ampoules with a ring of a break, a point and an intersection the knife ampullum or skarifikator do not put.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep at inaccessible to children.

Shelf life:

2 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LS-002174

Date of registration:26.08.2011 / 13.02.2014

Expiration Date:Unlimited

The owner of the registration certificate:BIOSINTEZ, PAO BIOSINTEZ, PAO Russia

Manufacturer: & nbsp

BIOSINTEZ, PAO Russia

Information update date: & nbsp27.09.2017

Illustrated instructions

Instructions

Asparkam-L (Asparcam-L)